重组人脑利钠肽与伊伐布雷定联合治疗慢性充血性心力衰竭的效果研究  

Study on the Efficacy of Recombinant Human Brain Natriuretic Peptide Combined with Ivabradine in the Treatment of Chronic Congestive Heart Failure

作　　者：黄鑫 HUANG Xin(Department of Cardiovascular Medicine,Yantai Port Hospital Co.,Ltd.,Yantai 264000,China)

机构地区：[1]烟台海港医院有限公司心血管内科,山东烟台264000

出　　处：《中国医药指南》2023年第13期79-82,共4页Guide of China Medicine

摘　　要：目的探讨重组人脑利钠肽(rhBNP)与伊伐布雷定联合治疗慢性充血性心力衰竭(CHF)的效果。方法2020年12月至2022年11月,选取此期间本院收治的CHF患者102例,以随机数字表分为对照组(51例)与研究组(51例)。对照组采用伊伐布雷定治疗,研究组在其基础上联合rhBNP治疗。针对两组患者的临床疗效、心功能指标[左室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室后壁厚度(LVPWD)、左室射血分数(LVEF)]、N末端脑钠肽前体(NT-proBNP)水平、肌钙蛋白T(cTnT)水平、C-反应蛋白(CRP)水平、白细胞介素-6(IL-6)水平,以及不良反应与明尼苏达心力衰竭生活质量问卷(MLHFQ)评分进行比较。结果两组治疗的总有效率比较,研究组结果高于对照组(P<0.05)。治疗4周后,研究组LVEF指标高于对照组,LVEDD、LVESD、LVPWD、cTnI、NT-proBNP、CRP、IL-6以及MLHFQ问卷评分均低于对照组(P<0.05)。两组治疗的不良反应发生率比较,结果未见显著性差异(P>0.05)。结论rhBNP与伊伐布雷定联合治疗CHF效果确切,可以有效改善患者的心功能,调节c TnI、NT-proBNP水平,抑制炎性反应,保障其生活质量,具有较高的临床应用价值。Objective To investigate the efficacy of recombinant human brain natriuretic peptide(rhBNP)combined with ivabradine in the treatment of chronic congestive heart failure(CHF).Methods From December 2020 to November 2022,102 CHF patients admitted to our hospital during this period were selected and randomly divided into a control group(51 cases)and a study group(51 cases)using a random number table.The control group was treated with ivabradine,while the study group was treated with rhBNP on the basis of it.Compare the clinical efficacy,cardiac function indicators[left ventricular end diastolic diameter(LVEDD),left ventricular posterior wall thickness(LVPWD),left ventricular end systolic diameter,(LVESD),left ventricular ejection fraction(LVEF)],N-terminal proBNP levels,troponin T(cTnT)levels,C-reactive protein(CRP)levels,interleukin-6(IL-6)levels,adverse reactions,and Minnesota Living with Heart Failure Questionnaire(MLHFQ)scores between two groups of patients.Results The total effective rate of the two groups of treatment was compared,and the results of the study group was higher than those of the control group(P<0.05).After 4 weeks of treatment,LVEF indicators in the study group was higher than those in the control group,LVEDD,LVESD,LVPWD,cTnI,NT-proBNP,CRP,IL-6 and MLHFQ score were lower than those the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups of treatment(P>0.05).Conclusion The combination of rhBNP and ivabradine is effective in treating CHF,which can effectively improve patients'heart function,regulate cTnI and NT proBNP levels,inhibiting inflammatory reactions,and ensure their quality of life.It has high clinical application value.

关 键 词：重组人脑利钠肽 伊伐布雷定 慢性充血性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]